US 12,234,280 B2
Anti-PHF-tau antibodies and uses thereof
Kristof Van Kolen, Haacht (BE); Marc Mercken, Turnhout (BE); Linda Barone, Exton, PA (US); Eilyn R. Lacy, Lansdowne, PA (US); Rupesh Nanjunda, Hatfield, PA (US); John Wheeler, Downington, PA (US); Jinquan Luo, Malvern, PA (US); and Marianne Borgers, Balen (BE)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Appl. No. 16/978,022
Filed by JANSSEN PHARMACEUTICA NV, Beerse (BE)
PCT Filed Mar. 4, 2019, PCT No. PCT/IB2019/051748
§ 371(c)(1), (2) Date Sep. 3, 2020,
PCT Pub. No. WO2019/171259, PCT Pub. Date Sep. 12, 2019.
Claims priority of provisional application 62/638,535, filed on Mar. 5, 2018.
Prior Publication US 2021/0002358 A1, Jan. 7, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 39/00 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01); C12N 15/62 (2006.01); C12N 15/85 (2006.01); G01N 33/563 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/18 (2013.01) [A61P 25/16 (2018.01); A61P 25/28 (2018.01); C12N 15/62 (2013.01); C12N 15/85 (2013.01); G01N 33/563 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/565 (2013.01); G01N 2800/2821 (2013.01); G01N 2800/2835 (2013.01)] 10 Claims
 
1. An isolated antibody or antigen-binding fragment thereof that binds to paired helical filament-tau (PHF-tau), comprising:
(a) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 15, and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 16;
(b) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 17, and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 18;
(c) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 19, and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 20;
(d) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 21, and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 22;
(e) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 23, and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 20; or
(f) a heavy chain variable region consisting of the amino acid sequence of SEQ ID NO: 24, and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 25.